Trial Profile

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and Pembrolizumab in Combination With Other Investigational Agents in Subjects With High Risk Non-muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Favezelimab/pembrolizumab (Primary) ; Pembrolizumab (Primary) ; Pembrolizumab+vibostolimab (Primary)
Indications Bladder cancer; Carcinoma
Focus Adverse reactions; Therapeutic Use
Acronyms KEYNOTE 057
Sponsors Merck Sharp & Dohme Corp.

20 Mar 2025 Effective as of Amendment 12, Cohort C was made exploratory, and all Cohort C outcome measures were made exploratory.
07 Jan 2025 Status changed from recruiting to active, no longer recruiting.
27 Jan 2024 Results from cohort c, presented at the 2024 Genitourinary Cancers Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com